June 08, 2015
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
- Goldman Sachs 36th Annual
Global Healthcare Conference -
- William Blair 35th Annual
Growth Stock Conference -
- Webcasts Available Through Gilead Corporate Website -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 8, 2015--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate
presentation will be webcast from two upcoming investor conferences: the
Goldman Sachs 36th Annual Global Healthcare Conference in
Rancho Palos Verdes and the William Blair 35th Annual Growth
Stock Conference in Chicago.
John F. Milligan, PhD, Gilead’s President and Chief Operating Officer,
will provide an overview of the company at the Goldman Sachs conference
on Tuesday, June 9 at 10:00 a.m. Pacific Time.
Robin L. Washington, Gilead’s Executive Vice President and Chief
Financial Officer, will provide an overview of the company at the
William Blair conference on Tuesday, June 9 at 9:30 a.m. Central Time.
The live webcast can be accessed at the company’s Investors page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be required to listen to the webcast. The replay will
be available for 14 days following the presentation.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150608006275/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936
Investor
Relations
